Copyright
©The Author(s) 2021.
World J Hepatol. Jul 27, 2021; 13(7): 731-746
Published online Jul 27, 2021. doi: 10.4254/wjh.v13.i7.731
Published online Jul 27, 2021. doi: 10.4254/wjh.v13.i7.731
Regimen | Dosing | Duration of regimen | Further guidance |
Somatostatin | Bolus of 500 μg, followed by 500 μg/h via continuous infusion (6 mg/50 mL, infusion rate of 4.2 mL/h) | 2-5 d | Bolus can be repeated in case of uncontrolled bleeding |
Terlipressin | Bolus of 2mg every 4 h for the first 24-48 h, followed by giving bolus of 1mg every 4 h; Or continuous infusion 2 mg/d; maximum 12 mg/d | 2-5 d | Be caution in patients with coronary artery disease, peripheral arterial occlusive disease hyponatremia (< 125 mmol/L), cardiac arrhythmia and severe asthma or chronic occlusive pulmonary disease |
Octreotide (somatostatin analogue) | Bolus of 50 μg, followed by 50 μg via continuous infusion | 2-5 d | Bolus can be repeated in case of uncontrolled bleeding |
- Citation: Pfisterer N, Unger LW, Reiberger T. Clinical algorithms for the prevention of variceal bleeding and rebleeding in patients with liver cirrhosis. World J Hepatol 2021; 13(7): 731-746
- URL: https://www.wjgnet.com/1948-5182/full/v13/i7/731.htm
- DOI: https://dx.doi.org/10.4254/wjh.v13.i7.731